Search the Newsreel

Swiss National Bank Grows Position in PTC Inc. $PTC

The Swiss National Bank increased its stake in PTC Inc. by 6.3% in the first quarter, bringing its total holdings to 348,900 shares valued at approximately $49.7 million. This move comes as PTC reported strong quarterly results, with EPS of $2.69 and revenue of …

Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know

PTC Therapeutics (PTCT) is expected to report a year-over-year increase in earnings on higher revenues for the quarter ended June 2026, despite a projected quarterly loss of $0.09 per share. The consensus EPS estimate has been revised 38.1% lower over the last 30 days. …

Rosenblatt Securities Maintains PTC Inc(PTC.US) With Buy Rating, Maintains Target Price $190

Rosenblatt Securities has reiterated its Buy rating for PTC Inc. (PTC.US) and maintained a price target of $190. This indicates a continued positive outlook from the firm regarding PTC's stock performance and valuation.

PTC Falls as Investors Weigh Upcoming Earnings and Ongoing Software Sector Pressure

PTC (PTC) stock experienced a decline as investors anticipated its upcoming earnings report and considered the broader pressures facing the software sector. The stock's performance this year has been modest, and it faces competition, macroeconomic headwinds, and a high interest rate environment. The article …

Hsbc Holdings PLC Acquires 37,502 Shares of PTC Inc. $PTC

HSBC Holdings PLC increased its stake in PTC Inc. by 11.8% in the first quarter, purchasing an additional 37,502 shares to bring its total holding to 356,219 shares valued at $50.7 million. PTC reported strong quarterly earnings, beating analyst estimates with an EPS of …

Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $120

Barclays has reiterated its Buy rating for PTC Therapeutics (PTCT.US) and maintained its price target at $120. This indicates the firm's continued confidence in the company's financial prospects. Investors can use this information as part of their broader research into PTCT.US.

PTC Inc (PTC) Stock Down 3.2% -- Now Undervalued? GF Score: 81/1

PTC Inc.'s stock dropped 3.2% to $120.77, marking a significant year-to-date decline, yet GuruFocus assesses it as significantly undervalued with a GF Value™ of $215.59. Despite a strong GF Score™ of 81/100, indicating high profitability and growth, concerns arise from its low momentum rank …

PTC India Financial Services hosting earnings call on 29 Jul 2026 at 16:00 IST

Behavioral Patterns of PTC and Institutional Flows

This article analyzes behavioral patterns and institutional flows for PTC (NYSE: PTC), indicating mixed sentiment and choppiness across different time horizons. It provides AI-generated trading strategies including long, breakout, and short positions, along with multi-timeframe signal analysis, support, and resistance levels. The report highlights …

PTCT Maintained by Wells Fargo -- Price Target Lowered to $93.00

Wells Fargo maintained its "Overweight" rating for PTC Therapeutics (PTCT) but lowered its price target from $95.00 to $93.00. GuruFocus's GF Value™ indicates the stock is 115.4% overvalued, with a current price of $78.59 against a GF Value™ of $36.48. The company's GF Score™ …

Is PTC Therapeutics (PTCT) Cheap On Fast Track News For PTC518?

PTC Therapeutics, Inc. (PTCT) received Fast Track designation for its PTC518 Huntington's disease program, prompting a re-evaluation of the stock. While a discounted cash flow model suggests significant undervaluation with a fair value of $253.95, the price-to-sales ratio is only slightly below peers, indicating …

PTC Inc. stock underperforms Friday when compared to competitors

Shares of PTC Inc. (PTC) dropped 2.35% on Friday, closing at $124.37. This underperformance occurred during a generally negative trading session, with the S&P 500 Index and Dow Jones Industrial Average also experiencing declines. The stock's fall ended a two-day winning streak for PTC.

What PTC (PTC)'s AI-CAD, PLM Partnerships, and Digital Health Push Means For Shareholders

PTC Inc. is advancing its position in AI-CAD, PLM, and digital health through various partnerships and initiatives, including a Digital Implant Engineering Center and the Onshape Labs AI program. These developments aim to embed PTC’s software deeper into critical engineering and clinical workflows, reinforcing …

PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced it will host a webcast conference call on Thursday, July 30, 2026, at 4:30 p.m. ET to report its second quarter 2026 financial results, and provide a business update and outlook. Individuals can access the live webcast via …

RBC Capital Maintains PTC Inc(PTC.US) With Buy Rating, Maintains Target Price $195

RBC Capital has reiterated its Buy rating on PTC Inc (PTC.US) and maintained its price target at $195. This indicates a continued positive outlook from the firm regarding PTC's stock performance.

PTC4945173 Bond Profile — Key Metrics

This article provides key metrics for the PTC4945173 bond issued by PTC Inc. It details important facts such as the issuer, issue date, maturity date, outstanding amount, face value, minimum denomination, and a 4.00% coupon rate. PTC Inc. is described as a global software …

PTC Therapeutics schedules second-quarter 2026 results webcast conference call

PTC Therapeutics is scheduled to report its second-quarter 2026 financial results on July 30, 2026. A webcast conference call will be held on the same day at 4:30 p.m. ET, with a replay available for 30 days. This news brief was generated by Public …

A Look at PTC Inc (PTC) After 3.0% Gain -- GF Value $216.09 vs P

PTC Inc (PTC) shares rose 3.0% to $127.39, trading significantly below its GF Value™ estimate of $216.09, indicating it is undervalued by 41.0%. The company boasts strong fundamentals with a GF Score™ of 81/100, particularly in profitability and growth, but shows weaknesses in valuation …

Form 4 PTC Therapeutics Inc For: 16 July By Investing.com

This article from Investing.com reports that a Form 4 filing for PTC Therapeutics Inc. was made on July 16, 2026. Form 4s disclose transactions by company insiders, but the article does not provide specific details about the transactions. The content primarily consists of market …

PTC Therapeutics (PTCT) CFO auto-sells 3,494 shares to cover RSU taxes

PTC Therapeutics' CFO, Pierre Gravier, automatically sold 3,494 shares of common stock at $80.35 per share on July 14, 2026. This transaction was executed to fulfill tax withholding obligations tied to the vesting of 6,500 RSUs. After this sale, Gravier directly holds 83,986 shares …

PTC (PTC) Stock Looks Undervalued On Earnings But Weighed By Execution Risk

PTC's stock has dropped 36.3% over the past year, leading to a valuation that appears undervalued based on earnings multiples, despite the company's focus on AI-enabled products. The company trades at a P/E of 11.4x, significantly below industry and peer averages, suggesting potential for …

PTC Therapeutics Sets July 30 Webcast for Business Update

PTC Therapeutics (NASDAQ: PTCT) announced it will host a webcast conference call on Thursday, July 30, 2026, at 4:30 p.m. ET to report its second quarter 2026 financial results and provide a business and outlook update. Investors can access the live webcast and replay …

PTC Therapeutics (PTCT) Gets a Buy from Bank of America Securities

Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on PTC Therapeutics (PTCT) with a $95.00 price target. This follows a similar Buy rating from J.P. Morgan, though RBC Capital maintained a Hold rating. The company recently reported a quarterly revenue of …

What PTC Therapeutics (PTCT)'s Q1 Beat and Sephience Outlook Shift Mean For Shareholders

PTC Therapeutics reported strong Q1 2026 earnings, surpassing analyst expectations, and a positive outlook for its rare disease therapy, Sephience. This has led to renewed optimism and analyst upgrades, despite pre-planned insider stock sales. The company's future investment narrative hinges on Sephience offsetting concentration …

Analysts’ Top Technology Picks: PTC (PTC), Bel Fuse Inc (BELFB)

This article highlights bullish sentiments from financial analysts on three technology stocks: PTC (PTC), Bel Fuse Inc (BELFB), and Apple (AAPL). It details the ratings and price targets from specific analysts, noting PTC has a Moderate Buy consensus, Bel Fuse Inc a Strong Buy, …

Cantor Fitzgerald reiterates Overweight on PTC Therapeutics stock

Cantor Fitzgerald has reiterated an Overweight rating and a $124 price target for PTC Therapeutics (NASDAQ:PTCT), citing a strong launch for its PKU treatment, Sephience. The firm plans to engage management to discuss Sephience's global expansion, potential FDA dialogue for votoplaln in Huntington's disease, …

PTC Inc. Earnings Preview: What to Expect

PTCIL Forecast — Price Target — Prediction for 2027

PTC Inc. Stock: Is PTC Underperforming the Technology Sector?

PTC Industries' (NSE:PTCIL) Shareholders May Want To Dig Deeper Than Statutory Profit

Why Is PTC Inc. (PTC) Down 6% Since Last Earnings Report?

Some May Be Optimistic About PTC India's (NSE:PTC) Earnings

With EPS Growth And More, PTC Industries (NSE:PTCIL) Makes An Interesting Case

PTC INC (NASDAQ:PTC) Fits Louis Navellier's "Little Book" Growth Stock Criteria

PTC Inc. Just Beat EPS By 29%: Here's What Analysts Think Will Happen Next

PTC Industries Limited (NSE:PTCIL) CEO Sachin Agarwal's holdings dropped 4.1% in value as a result of the recent pullback